Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

DiaMedica Therapeutics Inc. (DMAC) EBITDA (2018 - 2019)

DiaMedica Therapeutics (DMAC) has 2 years of EBITDA data on record, last reported at -$2.5 million in Q4 2019.

  • For Q4 2019, EBITDA fell 26.61% year-over-year to -$2.5 million; the TTM value through Dec 2019 reached -$10.6 million, down 85.68%, while the annual FY2024 figure was -$24.4 million, 26.56% down from the prior year.
  • EBITDA reached -$2.5 million in Q4 2019 per DMAC's latest filing, down from -$2.5 million in the prior quarter.
  • Across five years, EBITDA topped out at -$650000.0 in Q1 2018 and bottomed at -$3.2 million in Q1 2019.